Lexeo Therapeutics, Inc. Common Stock (LXEO) — Financial Flexibility Index
Lexeo Therapeutics, Inc. Common Stock (LXEO) has a Financial Flexibility Index of -0.89x as of June 2026. Free cash flow of $-17.59 Million (operating CF $-17.60 Million minus capex $7.00K) represents -1% of total liabilities ($19.84 Million). Check Lexeo Therapeutics, Inc. Common Stock (LXEO) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Lexeo Therapeutics, Inc. Common Stock Financial Flexibility Index (2020–2025)
Historical Financial Flexibility Index trend for Lexeo Therapeutics, Inc. Common Stock across 6 annual periods. For the full cash flow conversion analysis, see Lexeo Therapeutics, Inc. Common Stock cash conversion from operations.
Annual Financial Flexibility Index for Lexeo Therapeutics, Inc. Common Stock (2020–2025)
Year-by-year free cash flow to debt coverage for Lexeo Therapeutics, Inc. Common Stock. Explore debt repayment capacity of Lexeo Therapeutics, Inc. Common Stock to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -4.46x | $-98.16 Million | $-98.56 Million | $22.02 Million | ▼ -66.3% |
| 2024 | -2.68x | $-80.67 Million | $-81.15 Million | $30.10 Million | ▼ -18.7% |
| 2023 | -2.26x | $-59.33 Million | $-59.50 Million | $26.27 Million | ▼ -783.9% |
| 2022 | -0.26x | $-53.66 Million | $-54.56 Million | $210.03 Million | ▼ -11.8% |
| 2021 | -0.23x | $-43.99 Million | $-44.18 Million | $192.46 Million | ▼ -154.9% |
| 2020 | -0.09x | $-3.13 Million | $-3.13 Million | $34.95 Million | — |